The V275M mutation increases the ability of ClC-4 to form heterodimers with ClC-3b and is, thus, expected to increase endo-lysosomal ClC-4 Cl–/H+ transport levels; this mutation was identified in a patent with epilepsy and moderate-severe intellectual disability. Here, CLCN4 is linked to epilepsy.